Press "Enter" to skip to content

Cannabis Trade Can Be the Saviour for Big Pharma

With leisure packages quickly increasing within the US and overseas, it must be a shock that cannabis professionals are nonetheless equated with “drug pushers.” The individuals who draw these comparisons are sometimes the identical individuals who oppose the expanded entry of lab-examined cannabis merchandise. “We have to do extra analysis to uncover the potential hidden risks that cannabis absolutely possesses!” they cry—whereas not supporting something in the best way of analysis funding, or adjustments to regulation that may enable researchers to make use of one thing aside from the University of Mississippi extremely-schwag that federally funded researchers are required to.

The purpose of the leisure cannabis trade is to develop and develop markets for the authorized sale of a variety of cannabis (and hemp) merchandise. Whereas many within the profession have targets of wellness and different non-financial advantages, gross sales are the primary driver, as they’re in any capitalistic enterprise. As cannabis turns into more and more commodified, the “pusher” moniker appears outdated.

Which brings me to the, ahem, absolutely authorized pharmaceutical business. Latest information protection of one of many largest true drug pushers on this planet offers us different and sickening perception into how their product is promoted and offered. The dealers in the query are Purdue Pharma, and their product is Oxycontin—a drug that’s nationally accessible, with entry to publicity, promotion, and capital that cannabis is barred from.

Mission News Theme by Compete Themes.